Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance
See more from Benzinga
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings
Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.